M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 40 of 54
Caregiver Assessments of the Quality of Home Hospice Care
NCT00895024
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients
NCT00877773
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
NCT00871923
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
NCT00862680
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
NCT00861406
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
NCT00857389
BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets
NCT00872157
Patient-Reported Outcomes (PRO)-Based Palliative and Hospice Care Practice: A Qualitative Study
NCT00878267
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage
NCT00905034
Identification and Treatment of Depression
NCT00863200
Motion Correction of Positron Emission Tomography (PET) Data Using Amplitude Gating
NCT00843219
PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide
NCT00867477
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
NCT00726830
Cue Reactivity in Virtual Reality: The Role of Context
NCT00862927
Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
NCT00832429
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
NCT00880815
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
NCT00748215
Automated Pain Intervention for Underserved Minority Breast Cancer Patients
NCT00881010
FDG-PET-CT and Biomarkers in Esophageal Cancer
NCT00833625
Questionnaire and Fall Risk Assessment
NCT00836238
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
NCT00833807
Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)
NCT00829959
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
NCT00826449
M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) Symptom Management Program
NCT00827801
Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients
NCT00876499
PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma
NCT00828126
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
NCT00822770
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
NCT00360672
Enhancing Knowledge Implantable Cardioverter-Defibrillators (ICDs)
NCT00822965
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
NCT00810576
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
NCT00734526
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
NCT00824993
Spousal Support in Head and Neck Cancer
NCT00824252
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
NCT00813124
Body Image Functioning Among Surgically Treated Patients With Head and Neck Cancer
NCT00824174
Formative Study of Tailored Survivor Health Promotion
NCT00825240
Anderson Circulating Tumor Cell Burden (CTCB) Study
NCT00819832
Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy
NCT00824902
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
NCT00769483
Identifying the Role of Symptom Outcomes and Biomarkers in Survival in Patients With Metastatic Pancreatic Cancer
NCT00805688
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
NCT00787527
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
NCT00792077
Quality of Life After Esophagectomy for Cancer
NCT00798746
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
NCT00806507
Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
NCT00790452
Bendamustine in Acute Leukemia and MDS
NCT00790855
Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)
NCT00745732
Radiation Therapy and Cardiac Enzymes
NCT00777751
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
NCT00778375
Childhood Cancer Survivor Survey
NCT00788476
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.